Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 319

Next Previous
Drug Profile

A 319

Alternative Names: A-319

Latest Information Update: 20 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evive Biotech
  • Developer Evive Biotech; ITabMed
  • Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus
  • Phase 0 Rheumatoid arthritis

Most Recent Events

  • 20 Apr 2026 A 319 is still in phase I trials for B-cell lymphoma (Second-line therapy or greater) and Precursor B-cell lymphoblastic leukaemia-lymphoma in China (ITabMed Pipeline, April 2026) (CTR20210368)
  • 28 Feb 2026 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in China (IV, Infusion)
  • 02 Feb 2026 Shanxi Bethune Hospital plans a clinical trial for Precursor cell lymphoblastic leukaemia lymphoma (Second-line therapy or greater) (SC, Injection) in February 2026 (NCT07371533)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top